Trial Profile

Evaluation of Adherence Rate in Patients Receiving PegIntron Pen [peginterferon alfa-2b] / Rebetol [ribavirin] for Hepatitis C

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme; Schering-Plough

Most Recent Events

29 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
05 Jun 2009 Actual number of patients changed from 350 to 267 as reported by ClinicalTrials.gov.
21 Jul 2008 Status change

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com